Search clinical trials for: TMC435 (G006)

Total 414 results

University Of Perugia

Unknown

Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome

Painful Bladder Syndrome (PBS)

Italy
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Completed

Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer

Rectal Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Bayer

Terminated

Depocyt® With Sorafenib in Neoplastic Meningitis

Neoplastic Meningitis

United States
Hospital Universitario Pedro Ernesto

Completed

Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine (CONTROL)

Hypertension | Diabetes Mellitus

Brazil
Bayer

Terminated

Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib

Carcinoma, Renal Cell

United States
Tibotec Pharmaceuticals, Ireland

Completed

A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study

Human Immunodeficiency Virus Type 1
University of Copenhagen

Completed

GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations

Obesity

Denmark
Bayer

Completed

Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung | Lung Cancer

United States
Amphastar Pharmaceuticals, Inc.

Completed

Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006

Asthma | Chronic Obstructive Pulmonary Disease (COPD) | Bronchospasm

United States
Tibotec, Inc
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Completed

Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.

HIV

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Bayer; Genzyme, a Sanofi Company; Amgen; Georgia...

Completed

Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations

Leukemia | Acute Myelogenous Leukemia

United States
Amphastar Pharmaceuticals, Inc.

Completed

Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (A006-D)

Asthma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Study of Anti-HIV Therapy Intensification

HIV Infections

United States
M.D. Anderson Cancer Center

Not yet recruiting

A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

Refractory Acute Leukemia | Relapsed Acute Leukemia

United States
Janssen-Cilag International NV

Completed

A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients (SENSE)

Acquired Immunodeficiency Syndrome | HIV Infection | HIV

France, United Kingdom, Germany, Spain, Switzerland, Israel, Russian Federation, Austria, Hungary, Romania, Denmark
St Stephens Aids Trust

Completed

Pilot Study Switching Individuals Receiving EFV With Continuing Central Nervous System Toxicity to TMC125

HIV

United Kingdom
M.D. Anderson Cancer Center
Bayer

Completed

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
St. Jude Children's Research Hospital

Completed

Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

Leukemia | Refractory Solid Tumors

United States
Amphastar Pharmaceuticals, Inc.

Completed

Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation (A006-B3)

Asthma

United States
National Cancer Institute (NCI)

Completed

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Metastatic Gastric Cancer | Adenocarcinoma of the Gastroesophageal Junction | Advanced Unresectable Gastric Cancer

United States
National Cancer Institute (NCI)

Completed

Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
M.D. Anderson Cancer Center
Sabinsa Corporation

Withdrawn

Study of Curcumin, Vorinostat, and Sorafenib

Advanced Cancers
University Hospital, Bordeaux
University of Bordeaux

Completed

Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation (COVERAGEFrance)

Corona Virus Infection | Sars-CoV2

France
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

HIV Infections

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal... and other conditions

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Completed

Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Universitätsklinikum Hamburg-Eppendorf
German Research Foundation; University Hospital Tuebingen

Completed

Enhancement of Motor Function With Reboxetine and Transcranial Direct Current Stimulation (STIMBOX)

Cerebral Stroke

Germany
Bayer
Amgen

Completed

Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects

Metastatic Colorectal Cancer

Belgium, Italy, Poland, Spain, Russian Federation, United States, Hungary, Romania, United Kingdom, Ukraine
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Southwest Oncology Group; Cancer and Leukemia Group...

Completed

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery (ASSURE)

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage II Renal Cell Cancer AJCC v7 | Stage I Renal Cell Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
M.D. Anderson Cancer Center

Completed

Bevacizumab in Multiple Phase I Combinations

Advanced Cancer

United States
St. Jude Children's Research Hospital

Recruiting

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular Carcinoma | Pediatric Cancer | Malignant Solid Tumor | Fibrolamellar Carcinoma | Pediatric Solid Tumor | Refractory Solid Tumor

United States
National Cancer Institute (NCI)

Completed

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm | BRAF Gene Mutation

United States
National Cancer Institute (NCI)

Active, not recruiting

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Acute Myeloid Leukemia Post Cytotoxic Therapy

United States
French National Agency for Research on AIDS and...
Merck Sharp & Dohme LLC; Janssen-Cilag Tibotec

Completed

Clinical Trial to Assess the Efficacy of Darunavir/Ritonavir (DRV/r), Etravirine (ETV) and Raltegravir (MK-0518) in HIV Patients With Resistant Viruses (ANRS139 TRIO)

HIV Infections

France
Thomas Olencki
Schering-Plough

Terminated

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
M.D. Anderson Cancer Center

Active, not recruiting

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Advanced Cancer

United States
M.D. Anderson Cancer Center

Completed

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

Advanced Cancer | Solid Tumors

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
M.D. Anderson Cancer Center

Completed

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Solid Tumors

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
St. Jude Children's Research Hospital
Ohio State University; Arog Pharmaceuticals, Inc.

Completed

Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma AJCC v7 | Stage IIIC Hepatocellular Carcinoma AJCC v7 | Stage IV Hepatocellular Carcinoma AJCC v7 | Stage III Hepatocellular Carcinoma AJCC v7 and other conditions

United States, Canada, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Emory University

Terminated

AflacLL1901 (CHOA-AML)

Acute Myeloid Leukemia | AML, Childhood

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma | Stage III Skin Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Recurrent Mixed Phenotype Acute Leukemia | Acute Leukemia of Ambiguous Lineage | Acute Undifferentiated Leukemia | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia | Mixed Phenotype Acute Leukemia | Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified | Mixed Phenotype Acute Leukemia...

United States

Search clinical trials for: TMC435 (G006)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations